Korva is a scroll of the internet’s best ideas.
Cut the service that was growing
The business they ended
The startup sold epigenetic aging tests to longevity clinics that wanted to measure aging in their patients. That line grew, with lots of respect and lots of meetings, and the books said to keep it. The founders ended it anyway, because it felt like a distraction from a race to generate data.
That meant giving up revenue that arrived regularly and predictably. In exchange, the team put its time into improving its method, aiming for higher resolution at lower cost. The goal is data nobody else can generate, and from it the company's own assets, such as new diagnostics or new therapeutic assets.
Investors and the way back
The investors are angels well versed in biotech who have written first checks before, and none of them pushed back. The team also reached agreement among themselves first on the company they wanted to build and the risk they wanted to take.
The company has not left the clinic market for good. If it keeps improving its methods, it can come back to clinics with an even cheaper and better product.
How does a DNA methylation clock estimate age?
Biostatistician Steve Horvath, then at UCLA, published a multi-tissue age predictor in 2013. It reads methylation at 353 sites in the genome and combines them into a single estimate of age. The model was trained on thousands of samples from many tissue types. Later clocks were trained on health outcomes instead of calendar age.
Why do investors accept shrinking early revenue?
Most clinical-stage biotech companies report little or no product revenue until a drug is approved. Investors in that sector therefore value a company on its data, its assets, and its pipeline. Revenue from services can make a company look healthier on paper while pulling people away from building those assets. Biotech companies commonly fund this stretch with equity rounds and grants.
More from This Week in Startups
